GILDKite, A Gilead CompanyNot started yet
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Newly Diagnosed Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 750 (planned)
- Started
- Feb 2027
- Main results expected
- Mar 2039
- Fully finished
- Mar 2042
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Minimal Residual Disease (MRD)-Negative Complete Response (CR) or Stringent CR (sCR) Rate at 12 Months
Measured over: Up to 12 months
Progression-Free Survival (PFS)
Measured over: Up to 15 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07903506 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC